MANNKIND CORP, a biopharmaceutical company operating within the Health Care sector and specifically in the Biotechnology industry, recently disclosed a change in beneficial ownership through a Form 4 filing. This filing, submitted by Steven B. Binder, a director of the company, detailed a transaction involving the sale of a portion of his shares. The transaction was executed under a Rule 10B5-1 plan, which was established in December 2025. Despite the sale, Binder continues to hold a substantial block of MANNKIND CORP’s common stock.
The company, which trades on the Nasdaq under the symbol MNKD, is incorporated in Delaware. MANNKIND CORP specializes in the development and commercialization of therapeutic products aimed at treating various diseases, including diabetes, cancer, inflammatory, and autoimmune conditions. The recent transaction was conducted at a price within a narrow range, adhering to standard SEC reporting requirements.
As of September 30, 2026, MANNKIND CORP’s close price was $3.95. The company’s stock has experienced significant volatility over the past year, with a 52-week high of $6.51 on January 7, 2026, and a 52-week low of $2.23 on March 26, 2026. The market capitalization of MANNKIND CORP stands at $1.25 billion USD. The company’s price-to-earnings ratio is currently -26.81, reflecting its financial performance and market valuation.
This disclosure provides investors with updated information on the ownership structure of MANNKIND CORP, ensuring transparency and compliance with regulatory standards. The company’s ongoing efforts in the biopharmaceutical field continue to be a focal point for stakeholders, as it seeks to advance its therapeutic products and address critical health challenges.
